Biodexa Pharmaceuticals Income Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	-	-	-	0.38	0.7	0.58
Revenue Growth	-	-	-	-45.49%	20.93%	68.51%
Cost of Revenue	5.21	3.96	5.44	4.07	5.11	4.65
Gross Profit	-5.21	-3.96	-5.44	-3.69	-4.41	-4.08
Selling, General & Admin	4.2	4.84	3.79	4.34	4.54	2.95
Other Operating Expenses	-0.57	-0.15	-0.03	-0.01	-0.02	-0.02
Operating Expenses	3.63	4.68	3.76	4.33	4.52	2.92
Operating Income	-8.84	-8.65	-9.2	-8.01	-8.93	-7
Interest Expense	-0.15	-0.23	-0.17	-0.04	-0.05	-0.04
Interest & Investment Income	0.15	0.09	0.17	0.08	0.03	-
Other Non Operating Income (Expenses)	4.53	2.3	3.22	0.49	0.47	0.94
EBT Excluding Unusual Items	-4.32	-6.49	-5.98	-7.49	-8.49	-6.11
Pretax Income	-4.32	-6.49	-5.98	-7.49	-8.49	-6.11
Income Tax Expense	0.1	-0.11	-0.25	-0.41	-0.83	-0.65
Earnings From Continuing Operations	-4.42	-6.38	-5.73	-7.08	-7.66	-5.46
Net Income	-4.42	-6.38	-5.73	-7.08	-7.66	-5.46
Net Income to Common	-4.42	-6.38	-5.73	-7.08	-7.66	-5.46
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	0	0	-	-	-	-
Shares Outstanding (Diluted)	0	0	-	-	-	-
Shares Change	-	-	-	-	-	-
EPS (Basic)	-77.26	-465.48	-	-	-	-
EPS (Diluted)	-77.26	-465.48	-	-	-	-
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-6.91	-5.59	-12.27	-6.85	-7.11	-6.33
Free Cash Flow Per Share	-120.69	-407.80	-	-	-	-
Operating Margin	-	-	-	-2103.41%	-1277.83%	-1210.73%
Profit Margin	-	-	-	-1858.01%	-1095.28%	-944.64%
Free Cash Flow Margin	-	-	-	-1798.42%	-1017.17%	-1094.81%
EBITDA	-8.85	-8.59	-9.08	-7.87	-8.76	-6.79
D&A For EBITDA	-0.01	0.05	0.12	0.14	0.17	0.21
EBIT	-8.84	-8.65	-9.2	-8.01	-8.93	-7

SEC Filings: 10-K · 10-Q